<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CIDOFOVIR- cidofovir injection, solution </strong><br>Mylan Institutional LLC<br></p></div>
<h1><span class="Bold">Cidofovir Injection</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_128b46e7-8815-4603-b181-b4f5b5a551dd"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><span class="Bold">FOR INTRAVENOUS INFUSION ONLY.</span></p>
<p><span class="Bold">NOT FOR INTRAOCULAR INJECTION.</span></p>
<div class="Warning">
<a name="id_a73ae845-8a75-4888-877a-116196601dbc"></a><a name="section-1.1"></a><p></p>
<h2> WARNING </h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">RENAL IMPAIRMENT</span> IS THE MAJOR TOXICITY OF CIDOFOVIR INJECTION. CASES OF <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">ACUTE RENAL FAILURE</span> RESULTING IN DIALYSIS AND/OR CONTRIBUTING TO <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span> HAVE OCCURRED WITH AS FEW AS ONE OR TWO DOSES OF CIDOFOVIR INJECTION. TO REDUCE POSSIBLE <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span>, INTRAVENOUS PREHYDRATION WITH NORMAL SALINE AND ADMINISTRATION OF PROBENECID MUST BE USED WITH EACH CIDOFOVIR INJECTION INFUSION. RENAL FUNCTION (SERUM CREATININE AND URINE PROTEIN) MUST BE MONITORED WITHIN 48 HOURS PRIOR TO EACH DOSE OF CIDOFOVIR INJECTION AND THE DOSE OF CIDOFOVIR INJECTION MODIFIED FOR CHANGES IN RENAL FUNCTION AS APPROPRIATE (SEE <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>). CIDOFOVIR INJECTION IS CONTRAINDICATED IN PATIENTS WHO ARE RECEIVING OTHER NEPHROTOXIC AGENTS.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">NEUTROPENIA</span> HAS BEEN OBSERVED IN ASSOCIATION WITH CIDOFOVIR INJECTION TREATMENT. THEREFORE, NEUTROPHIL COUNTS SHOULD BE MONITORED DURING CIDOFOVIR INJECTION THERAPY. </span></p>
<p><span class="Bold">CIDOFOVIR INJECTION IS INDICATED ONLY FOR THE TREATMENT OF <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV RETINITIS</span> IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">ACQUIRED IMMUNODEFICIENCY SYNDROME</span>.</span></p>
<p><span class="Bold">IN ANIMAL STUDIES CIDOFOVIR WAS CARCINOGENIC, TERATOGENIC AND CAUSED HYPOSPERMIA (SEE <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ffb15641-e578-488a-b2ef-6a53f18d8250">CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY</a>).</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_d0ffc508-4bba-40b3-b622-79aba1701eaa"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">The chemical name of cidofovir is 1-[(<span class="Italics">S</span>)-3-hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate (HPMPC), with the molecular formula of C<span class="Sub">8</span>H<span class="Sub">14</span>N<span class="Sub">3</span>O<span class="Sub">6</span>P•2H<span class="Sub">2</span>O and a molecular weight of 315.22 (279.19 for anhydrous). The chemical structure is:</p>
<div class="Figure">
<a name="id257"></a><img alt="Cidofovir Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9&amp;name=cdf09920-bfe5-407c-921f-f4aefca3e29e-01.jpg">
</div>
<p>Cidofovir is a white crystalline powder with an aqueous solubility of ≥ 170 mg/mL at pH 6 to 8 and a log P (octanol/aqueous buffer, pH 7.1) value of -3.3.</p>
<p>Cidofovir injection is a sterile, hypertonic aqueous solution for intravenous infusion only. The solution is clear and colorless. It is supplied in clear glass vials, each containing 375 mg of anhydrous cidofovir in 5 mL aqueous solution at a concentration of 75 mg/mL. The formulation is pH-adjusted to 7.4 with sodium hydroxide and/or hydrochloric acid and contains no preservatives. The appropriate volume of cidofovir injection must be removed from the single-use vial and diluted prior to administration (see <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_2533240e-e334-4e28-b4a4-e6d0295a54ee"></a><a name="section-3"></a><p></p>
<h1>MICROBIOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_871dadf0-2fbd-4ea5-af08-b715fd114ffa"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Cidofovir suppresses cytomegalovirus (CMV) replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of CMV DNA polymerase by cidofovir diphosphate, the active intracellular metabolite of cidofovir. Cidofovir diphosphate inhibits herpesvirus polymerases at concentrations that are 8- to 600-fold lower than those needed to inhibit human cellular DNA polymerases alpha, beta, and gamma<span class="Sup">1, 2, 3</span>. Incorporation of cidofovir into the growing viral DNA chain results in reductions in the rate of viral DNA synthesis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7d71e005-5294-4db2-a188-39e5c1e2afde"></a><a name="section-3.2"></a><p></p>
<h2>In Vitro Susceptibility</h2>
<p class="First">Cidofovir is active <span class="Italics">in vitro</span> against a variety of laboratory and clinical isolates of CMV and other herpesviruses (Table 1). Controlled clinical studies of efficacy have been limited to patients with AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>.</p>
<a name="_Refid_aebb594c-22f7-4579-972c-5fd6bb53f"></a><table>
<caption><span>Table 1: Cidofovir Inhibition of Virus Multiplication in Cell Culture</span></caption>
<col width="25%">
<col width="13%">
<thead><tr class="First Last">
<th class="Botrule Toprule"><span class="Bold"><span class="Underline">Virus</span></span></th>
<th class="Botrule Toprule"><span class="Bold"><span class="Underline">IC<span class="Sub">50</span> (µM)</span></span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Wild-type CMV Isolates</p></td>
<td class="Toprule" align="center" valign="top"><p class="First">0.5 to 2.8</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">HSV-1, HSV-2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">12.7 to 31.7</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7d80341f-63b8-4d08-baec-b6a7bad70659"></a><a name="section-3.3"></a><p></p>
<h2>Resistance</h2>
<p class="First">CMV isolates with reduced susceptibility to cidofovir have been selected <span class="Italics">in vitro</span> in the presence of high concentrations of cidofovir<span class="Sup">4</span>. IC<span class="Sub">50</span> values for selected resistant isolates ranged from 7 to 15 µM.</p>
<p>There are insufficient data at this time to assess the frequency or the clinical significance of the development of resistant isolates following cidofovir injection administration to patients.</p>
<p>The possibility of viral resistance should be considered for patients who show a poor clinical response or experience recurrent <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression during therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c5a99116-e33c-4545-be4f-0d76c61f8183"></a><a name="section-3.4"></a><p></p>
<h2>Cross-Resistance</h2>
<p class="First">Cidofovir-resistant isolates selected <span class="Italics">in vitro</span> following exposure to increasing concentrations of cidofovir were assessed for susceptibility to ganciclovir and foscarnet<span class="Sup">4</span>. All were cross-resistant to ganciclovir, but remained susceptible to foscarnet. Ganciclovir- or ganciclovir/foscarnet-resistant isolates that are cross resistant to cidofovir have been obtained from drug naive patients and from patients following ganciclovir or ganciclovir/ foscarnet therapy. To date, the majority of ganciclovir-resistant isolates are UL97 gene product (phosphokinase) mutants and remain susceptible to cidofovir<span class="Sup">5</span>. Reduced susceptibility to cidofovir, however, has been reported for DNA polymerase mutants of CMV which are resistant to ganciclovir<span class="Sup">6–9</span>. To date, all clinical isolates which exhibit high level resistance to ganciclovir, due to mutations in both the DNA polymerase and UL97 genes, have been shown to be cross-resistant to cidofovir. Cidofovir is active against some, but not all, CMV isolates which are resistant to foscarnet<span class="Sup">10–12</span>. The incidence of foscarnet-resistant isolates that are resistant to cidofovir is not known. </p>
<p>A few triple-drug resistant isolates have been described. Genotypic analysis of two of these triple-resistant isolates revealed several point mutations in the CMV DNA polymerase gene. The clinical significance of the development of these cross-resistant isolates is not known. </p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_ab0c6806-374b-4c5a-ad28-fa6f3e88dbbd"></a><a name="section-4"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3038e840-245d-4994-be57-bc397c5402f1"></a><a name="section-4.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Cidofovir injection must be administered with probenecid. The pharmacokinetics of cidofovir, administered both without and with probenecid, are described below. </p>
<p>The pharmacokinetics of cidofovir without probenecid were evaluated in 27 HIV-infected patients with or without asymptomatic <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span>. Dose independent pharmacokinetics were demonstrated after one hr infusions of 1 (n = 5), 3 (n = 10), 5 (n = 2) and 10 (n = 8) mg/kg (see <a href="#_Refid_43308fdb-c4e9-4d8a-a00f-d01e68729">Table 2</a> for pharmacokinetic parameters). There was no evidence of cidofovir accumulation after 4 weeks of repeated administration of 3 mg/kg/week (n = 5) without probenecid. In patients with normal renal function, approximately 80% to 100% of the cidofovir injection dose was recovered unchanged in urine within 24 hr (n = 27). The renal clearance of cidofovir was greater than creatinine clearance, indicating renal tubular secretion contributes to the elimination of cidofovir. </p>
<p> The pharmacokinetics of cidofovir administered with probenecid were evaluated in 12 HIV-infected patients with or without asymptomatic <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV infection</span> and ten patients with relapsing <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. Dose independent pharmacokinetics were observed for cidofovir, administered with probenecid, after one hr infusions of 3 (n = 12), 5 (n = 6), and 7.5 (n = 4) mg/kg (see Table 2). Approximately 70% to 85% of the cidofovir injection dose administered with concomitant probenecid was excreted as unchanged drug within 24 hr. When cidofovir injection was administered with probenecid, the renal clearance of cidofovir was reduced to a level consistent with creatinine clearance, suggesting that probenecid blocks active renal tubular secretion of cidofovir.</p>
<a name="_Refid_43308fdb-c4e9-4d8a-a00f-d01e68729"></a><table>
<caption><span>Table 2: Cidofovir Pharmacokinetic Parameters Following 3 and 5 mg/kg Infusions, Without and With Probenecid<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="22%">
<col width="16%">
<col width="14%">
<col width="15%">
<col width="15%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule"><span class="Bold">PARAMETERS</span></th>
<th class="Botrule Rrule Toprule" colspan="2">
<span class="Bold">CIDOFOVIR INJECTION </span><br><span class="Bold"> ADMINISTERED </span><br><span class="Bold">WITHOUT PROBENECID</span>
</th>
<th class="Botrule Rrule Toprule" colspan="2">
<span class="Bold">CIDOFOVIR INJECTION </span><br><span class="Bold">ADMINISTERED WITH </span><br><span class="Bold">PROBENECID</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule Rrule"><span class="Bold"> </span></th>
<th class="Botrule Rrule">
<span class="Bold">3 mg/kg </span><br><span class="Bold">(n = 10)</span>
</th>
<th class="Botrule Rrule">
<span class="Bold">5 mg/kg </span><br><span class="Bold">(n = 2)</span>
</th>
<th class="Botrule Rrule">
<span class="Bold">3 mg/kg </span><br><span class="Bold">(n = 12)</span>
</th>
<th class="Botrule Rrule">
<span class="Bold">5 mg/kg </span><br><span class="Bold">(n = 6)</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>See <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">AUC (mcg∙hr/mL)</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">20.0 ± 2.3</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">28.3</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">25.7 ± 8.5</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">40.8 ± 9.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (end of infusion) <br>(mcg/mL)</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">7.3 ± 1.4</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">11.5</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">9.8 ± 3.7</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">19.6 ± 7.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Vdss (mL/kg)</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">537 ± 126 <br>(n = 12)</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">410 ± 102 <br>(n = 18)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clearance <br>(mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">179 ± 23.1 <br>(n = 12)</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">148 ± 38.8 <br>(n = 18)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Renal Clearance <br>(mL/min/1.73 m<span class="Sup">2</span>)</p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">150 ± 26.9 <br>(n = 12) </p></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top"><p class="First">98.6 ± 27.9 <br>(n = 11)</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">In vitro</span>, cidofovir was less than 6% bound to plasma or serum proteins over the cidofovir concentration range 0.25 to 25 mcg/mL. CSF concentrations of cidofovir following intravenous infusion of cidofovir injection 5 mg/kg with concomitant probenecid and intravenous hydration were undetectable (&lt; 0.1 mcg/mL, assay detection threshold) at 15 minutes after the end of a one hr infusion in one patient whose corresponding serum concentration was 8.7 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8bfb14a0-2ddd-43d3-892d-7bd9650edd01"></a><a name="section-4.2"></a><p></p>
<h2>DRUG-DRUG INTERACTIONS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3450b992-1548-4d53-a317-4a8b6a603162"></a><a name="section-4.2.1"></a><p></p>
<h3>Zidovudine</h3>
<p class="First">The pharmacokinetics of zidovudine were evaluated in ten patients receiving zidovudine alone or with intravenous cidofovir (without probenecid). There was no evidence of an effect of cidofovir on the pharmacokinetics of zidovudine.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cfb50e96-0b26-4e70-89e6-df64196c7500"></a><a name="section-4.3"></a><p></p>
<h2>SPECIAL POPULATIONS</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0a38b927-a1e9-40ab-8976-f0a2419adbf2"></a><a name="section-4.3.1"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">Pharmacokinetic data collected from subjects with creatinine clearance values as low as 11 mL/min indicate that cidofovir clearance decreases proportionally with creatinine clearance.</p>
<p>High-flux hemodialysis has been shown to reduce the serum levels of cidofovir by approximately 75%.</p>
<p>Initiation of therapy with cidofovir injection is contraindicated in patients with serum creatinine &gt; 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>) (see <a href="#i4i_contraindications_id_3c964b31-bd5b-4c97-882a-2249cbdb5caa">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e80dac5-0735-4061-9aef-e40204f9952e"></a><a name="section-4.3.2"></a><p></p>
<h3>Geriatric/Gender/Race</h3>
<p class="First">The effects of age, gender, and race on cidofovir pharmacokinetics have not been investigated.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_7654bda9-04ab-477d-bfbe-0c0145ea45b2"></a><a name="section-5"></a><p></p>
<h1>INDICATION AND USAGE</h1>
<p class="First">Cidofovir is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> in patients with <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immunodeficiency syndrome</span> (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER <span class="product-label-link" type="condition" conceptid="440032" conceptname="Cytomegalovirus infection">CMV INFECTIONS</span> (SUCH AS <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">PNEUMONITIS</span> OR <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">GASTROENTERITIS</span>), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_429b1b59-4c96-4263-8e28-675c03b81961"></a><a name="section-6"></a><p></p>
<h1>DESCRIPTION OF CLINICAL TRIALS</h1>
<p class="First">Three phase II/III controlled trials of cidofovir injection have been conducted in HIV-infected patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7df04da-72f8-48ea-9601-054fabff5f3e"></a><a name="section-6.1"></a><p></p>
<h2>Delayed Versus Immediate Therapy (Study 105)</h2>
<p class="First">In stage 1 of this open-label trial, conducted by the Studies of the Ocular Complications of AIDS (SOCA) Clinical Research Group, 29 previously untreated patients with peripheral <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week) or to have cidofovir injection delayed until progression of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span><span class="Sup">13</span>. In stage 2 of this trial, an additional 35 previously untreated patients with peripheral <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week), or to have cidofovir injection delayed until progression of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>. Of the 64 patients in this study, 12 were randomized to 5 mg/kg maintenance therapy, 26 to 3 mg/kg maintenance therapy, and 26 to delayed therapy. Of the 12 patients enrolled in the 5 mg/kg maintenance group, five patients progressed, five patients discontinued therapy and two patients had no progression at study completion. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] time to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression was not reached (25, not reached) for the 5 mg/kg maintenance group. Median (95% CI) time to the alternative endpoint of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression or study drug discontinuation was 44 days (24, 207) for the 5 mg/kg maintenance group. Patients receiving 5 mg/kg maintenance had delayed time to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression compared to patients receiving 3 mg/kg maintenance or deferred therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_de1c50d7-d548-412a-a024-22fa158784e5"></a><a name="section-6.2"></a><p></p>
<h2>Delayed Versus Immediate Therapy (Study 106)</h2>
<p class="First">In an open-label trial, 48 previously untreated patients with peripheral <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have cidofovir injection delayed until progression of <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span><span class="Sup">14</span>. Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received cidofovir injection for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies.</p>
<a name="_Refid_84d4a9a4-9d2a-4a5b-b9c7-b095e97a5"></a><table>
<caption><span>Table 3: Patient Characteristics and Disposition (Study 106)</span></caption>
<col width="53%">
<col width="22%">
<col width="19%">
<thead><tr class="First Last">
<th class="Botrule Toprule"><span class="Bold"> </span></th>
<th class="Botrule Toprule">
<span class="Bold">Immediate Therapy </span><br><span class="Bold">(n = 25)</span>
</th>
<th class="Botrule Toprule">
<span class="Bold">Delayed Therapy </span><br><span class="Bold">(n = 23)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>One patient died 2 weeks after withdrawing consent.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Two patients on immediate therapy were diagnosed with CMV disease and discontinued from study. One patient on delayed therapy was diagnosed with CMV gastrointestinal disease.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> progression not confirmed by retinal photography.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" valign="top"><p class="First"><span class="Underline">Baseline Characteristics</span></p></td>
<td class="Toprule" valign="top"></td>
<td class="Toprule" valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First">Age (years)</p></td>
<td align="center" valign="top"><p class="First">38</p></td>
<td align="center" valign="top"><p class="First">38</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Sex (M/F)</p></td>
<td align="center" valign="top"><p class="First">24/1</p></td>
<td align="center" valign="top"><p class="First">22/1</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Median CD4 Cell Count</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">9</p></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="Underline">Endpoints</span></p></td>
<td valign="top"></td>
<td valign="top"></td>
</tr>
<tr>
<td valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV Retinitis</span> Progression</p></td>
<td align="center" valign="top"><p class="First">10</p></td>
<td align="center" valign="top"><p class="First">18</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Discontinued Due to Adverse Event</p></td>
<td align="center" valign="top"><p class="First">6</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Withdrew Consent</p></td>
<td align="center" valign="top"><p class="First">3<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td align="center" valign="top"><p class="First">1</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Discontinued Due to Intercurrent Illness</p></td>
<td align="center" valign="top"><p class="First">2<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td align="center" valign="top"><p class="First">1<a href="#footnote-3" class="Sup">†</a></p></td>
</tr>
<tr>
<td valign="top"><p class="First">Discontinued Based on Ophthalmological Examination</p></td>
<td align="center" valign="top"><p class="First">1<a name="footnote-reference-4" href="#footnote-4" class="Sup">‡</a></p></td>
<td align="center" valign="top"><p class="First">1<a href="#footnote-4" class="Sup">‡</a></p></td>
</tr>
<tr>
<td valign="top"><p class="First">No Progression at Study Completion</p></td>
<td align="center" valign="top"><p class="First">1</p></td>
<td align="center" valign="top"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"><p class="First">Not Evaluable at Baseline</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">2</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95aef5cb-66d4-4633-a177-93621ac9253e"></a><a name="section-6.3"></a><p></p>
<h2>Dose-Response Study of Cidofovir Injection (Study 107)</h2>
<p class="First">In an open-label trial, 100 patients with relapsing <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> were randomized to receive 5 mg/kg once a week for 2 weeks and then either 5 mg/kg (n = 49) or 3 mg/kg (n = 51) every other week. Enrolled patients had been diagnosed with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy. Eighty-four of the 100 patients were considered evaluable for progression by serial retinal photographs (43 randomized to 5 mg/kg and 41 randomized to 3 mg/kg). Twenty-six and 21 patients discontinued therapy due to either an adverse event, intercurrent illness, excluded medication, or withdrawn consent in the 5 mg/kg and 3 mg/kg groups, respectively. Thirty-eight of the 100 randomized patients had progressed according to masked assessment of serial retinal photographs (13 randomized to 5 mg/kg and 25 randomized to 3 mg/kg). Using retinal photographs, the median (95% CI) times to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression for the 5 mg/kg and 3 mg/kg groups were 115 days (70, not reached) and 49 days (35, 52), respectively. This difference was statistically significant. Similar to Study 106, the median time to <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression for the 5 mg/kg group was difficult to precisely estimate due to the limited number of patients remaining on treatment over time (4 of the 49 patients in the 5 mg/kg group were treated for 115 days or longer). Median (95% CI) times to the alternative endpoint of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> progression or study drug discontinuation were 49 days (38, 63) and 35 days (27, 39) for the 5 mg/kg and 3 mg/kg groups, respectively. This difference was statistically significant.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3c964b31-bd5b-4c97-882a-2249cbdb5caa"></a><a name="section-7"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Initiation of therapy with cidofovir injection is contraindicated in patients with a serum creatinine &gt; 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>).</p>
<p> Cidofovir injection is contraindicated in patients receiving agents with nephrotoxic potential. Such agents must be discontinued at least seven days prior to starting therapy with cidofovir injection.</p>
<p>Cidofovir injection is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to cidofovir.</p>
<p>Cidofovir injection is contraindicated in patients with a history of clinically severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to probenecid or other sulfa-containing medications. </p>
<p>Direct intraocular injection of cidofovir injection is contraindicated; direct injection of cidofovir has been associated with <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, ocular hypotony, and permanent impairment of vision.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_7790e239-8cd5-4765-ac00-7d686751bf4f"></a><a name="section-8"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_94d0eb26-0014-4fd9-9737-740da39e4d2a"></a><a name="section-8.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span></h2>
<p class="First">Dose dependent <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> is the major dose-limiting toxicity related to cidofovir injection administration. Cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> resulting in dialysis and/or contributing to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have occurred with as few as one or two doses of cidofovir injection. Renal function (serum creatinine and urine protein) must be monitored within 48 hours prior to each dose of cidofovir injection. Dose adjustment or discontinuation is required for changes in renal function (serum creatinine and/or urine protein) while on therapy. <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>, as measured by urinalysis in a clinical laboratory, may be an early indicator of cidofovir injection-related <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Continued administration of cidofovir injection may lead to additional proximal tubular cell injury, which may result in <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, decreases in serum phosphate, uric acid, and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, elevations in serum creatinine, and/or <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, in some cases, resulting in the need for dialysis. Patients with these adverse events occurring concurrently and meeting a criteria of Fanconi's syndrome have been reported. Renal function that did not return to baseline after drug discontinuation has been observed in clinical studies of cidofovir injection.</p>
<p>Intravenous normal saline hydration and oral probenecid must accompany each cidofovir injection infusion. Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (see <a href="#i4i_precautions_id_13f5f7d3-48d5-4846-ac72-5d0d810fec71">PRECAUTIONS</a>). The safety of cidofovir injection has not been evaluated in patients receiving other known potentially nephrotoxic agents, such as intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents (see <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f0d6658-bad7-468f-89cc-b4b450014fab"></a><a name="section-8.2"></a><p></p>
<h2>Preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Initiation of therapy with cidofovir injection is contraindicated in patients with a baseline serum creatinine &gt; 1.5 mg/dL, a creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88a38147-0107-4f57-91bf-c86326d1e6d8"></a><a name="section-8.3"></a><p></p>
<h2>Hematological Toxicity</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> may occur during cidofovir injection therapy. Neutrophil count should be monitored while receiving cidofovir injection therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d0c14a0-6873-4b93-92a0-4a6b9b402e2b"></a><a name="section-8.4"></a><p></p>
<h2>Decreased Intraocular Pressure/Ocular Hypotony</h2>
<p class="First">Decreased intraocular pressure may occur during cidofovir injection therapy, and in some instances has been associated with decreased visual acuity. Intraocular pressure should be monitored during cidofovir injection therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d7f45904-306f-477c-9b20-0cc83302aba5"></a><a name="section-8.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Decreased serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> associated with proximal tubule injury and renal <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span> syndrome (including Fanconi's syndrome) have been reported in patients receiving cidofovir injection (see <a href="#i4i_adverse_effects_id_c49376b6-119a-40e2-9fb7-4c19cd155583">ADVERSE REACTIONS</a>). Cases of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in association with liver dysfunction and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in patients receiving cidofovir injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_13f5f7d3-48d5-4846-ac72-5d0d810fec71"></a><a name="section-9"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_fd381a46-7293-44e8-86f9-d7438daee1ce"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">Due to the potential for increased <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>, doses greater than the recommended dose must not be administered and the frequency or rate of administration must not be exceeded (see <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</p>
<p>Cidofovir injection is formulated for intravenous infusion only and must not be administered by intraocular injection. Administration of cidofovir injection by infusion must be accompanied by oral probenecid and intravenous saline prehydration (see <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_065eb6be-9145-4e2e-b880-5e91a6af9c4d"></a><a name="section-9.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span>/<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> or <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> was reported in clinical trials and during postmarketing in patients receiving cidofovir injection therapy. Treatment with topical corticosteroids with or without topical cycloplegic agents should be considered. Patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>/<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> during cidofovir injection therapy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_3975786b-dfb4-4c25-bd31-3e9ef00af2a7"></a><a name="section-9.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be advised that cidofovir injection is not a cure for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, and that they may continue to experience progression of <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span> during and following treatment. Patients receiving cidofovir injection should be advised to have regular follow-up ophthalmologic examinations. Patients may also experience other manifestations of CMV disease despite cidofovir injection therapy.</p>
<p>HIV-infected patients may continue taking antiretroviral therapy, but those taking zidovudine should be advised to temporarily discontinue zidovudine administration or decrease their zidovudine dose by 50%, on days of cidofovir injection administration only, because probenecid reduces metabolic clearance of zidovudine.</p>
<p>Patients should be informed of the major toxicity of cidofovir injection, namely <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and that dose modification, including reduction, interruption, and possibly discontinuation, may be required. Close monitoring of renal function (routine urinalysis and serum creatinine) while on therapy should be emphasized.</p>
<p>The importance of completing a full course of probenecid with each cidofovir injection dose should be emphasized. Patients should be warned of potential adverse events caused by probenecid (e.g., <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>). <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> may include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Administration of probenecid after a meal or use of antiemetics may decrease the <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> or therapeutic antihistamines and/or acetaminophen can be used to ameliorate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.</p>
<p>Patients should be advised that cidofovir causes tumors, primarily mammary adenocarcinomas, in rats. Cidofovir injection should be considered a potential carcinogen in humans (see <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_ffb15641-e578-488a-b2ef-6a53f18d8250">Carcinogenesis, Mutagenesis and Impairment of Fertility</a>). Women should be advised of the limited enrollment of women in clinical trials of cidofovir injection.</p>
<p>Patients should be advised that cidofovir injection caused reduced testes weight and hypospermia in animals. Such changes may occur in humans and cause <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>. Women of childbearing potential should be advised that cidofovir is embryotoxic in animals and should not be used during pregnancy. Women of childbearing potential should be advised to use effective contraception during and for one month following treatment with cidofovir injection. Men should be advised to practice barrier contraceptive methods during and for 3 months after treatment with cidofovir injection.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_31e061ab-1bb1-443d-a107-96093afb475a"></a><a name="section-9.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20f0bf44-6734-4d88-82a5-b30c4f4d4a72"></a><a name="section-9.4.1"></a><p></p>
<h3>Probenecid</h3>
<p class="First">Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine). Concomitant medications should be carefully assessed. Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of cidofovir injection infusion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_954f2e89-f116-4246-bd03-4847142de266"></a><a name="section-9.4.2"></a><p></p>
<h3>Nephrotoxic Agents</h3>
<p class="First">Concomitant administration of cidofovir injection and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and nonsteroidal anti-inflammatory agents] is contraindicated. Such agents must be discontinued at least 7 days prior to starting therapy with cidofovir injection.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_ffb15641-e578-488a-b2ef-6a53f18d8250"></a><a name="section-9.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">Chronic, 2-year carcinogenicity studies in rats and mice have not been carried out to evaluate the carcinogenic potential of cidofovir. However, a 26-week toxicology study evaluating once weekly subscapular subcutaneous injections of cidofovir in rats was terminated at 19 weeks because of the induction, in females, of palpable <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span>, the first of which was detected after six doses. The <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">masses</span> were diagnosed as mammary adenocarcinomas which developed at doses as low as 0.6 mg/kg/week, equivalent to 0.04 times the human systemic exposure at the recommended intravenous cidofovir injection dose based on AUC comparisons.</p>
<p>In a 26-week intravenous toxicology study in which rats received 0.6, 3, or 15 mg/kg cidofovir once weekly, a significant increase in mammary adenocarcinomas in female rats as well as a significant incidence of Zymbal's gland carcinomas in male and female rats were seen at the high dose but not at the lower two doses. The high dose was equivalent to 1.1 times the human systemic exposure at the recommended dose of cidofovir injection, based on comparisons of AUC measurements. In light of the results of these studies, cidofovir should be considered to be a carcinogen in rats as well as a potential carcinogen in humans.</p>
<p>Cynomolgus monkeys received intravenous cidofovir, alone and in conjunction with concomitant oral probenecid, intravenously once weekly for 52 weeks at doses resulting in exposures of approximately 0.7 times the human systemic exposure at the recommended dose of cidofovir injection. No tumors were detected. However, the study was not designed as a carcinogenicity study due to the small number of animals at each dose and the short duration of treatment.</p>
<p>No mutagenic response was observed in microbial mutagenicity assays involving <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> (Ames) and <span class="Italics">Escherichia coli</span> in the presence and absence of metabolic activation. An increase in micronucleated polychromatic erythrocytes <span class="Italics">in vivo</span> was seen in mice receiving ≥ 2000 mg/kg, a dosage approximately 65-fold higher than the maximum recommended clinical intravenous cidofovir injection dose based on body surface area estimations. Cidofovir induced chromosomal aberrations in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro</span> without metabolic activation. At the four cidofovir levels tested, the percentage of damaged metaphases and number of aberrations per cell increased in a concentration-dependent manner.</p>
<p>Studies showed that cidofovir caused inhibition of spermatogenesis in rats and monkeys. However, no adverse effects on fertility or reproduction were seen following once weekly intravenous injections of cidofovir in male rats for 13 consecutive weeks at doses up to 15 mg/kg/week (equivalent to 1.1 times the recommended human dose based on AUC comparisons). Female rats dosed intravenously once weekly at 1.2 mg/kg/week (equivalent to 0.09 times the recommended human dose based on AUC) or higher, for up to 6 weeks prior to mating and for 2 weeks post mating had decreased litter sizes and live births per litter and increased early resorptions per litter. Peri- and post-natal development studies in which female rats received subcutaneous injections of cidofovir once daily at doses up to 1.0 mg/kg/day from day 7 of gestation through day 21 postpartum (approximately 5 weeks) resulted in no adverse effects on viability, growth, behavior, sexual maturation or reproductive capacity in the offspring.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_b83c47d0-5c52-4f3c-a9b2-60959080a805"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_4a9f8ef1-d605-4cf6-a773-6b20bb44b044"></a><a name="section-9.6.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category C</h3>
<p class="First">Cidofovir was embryotoxic (reduced fetal body weights) in rats at 1.5 mg/kg/day and in rabbits at 1.0 mg/kg/day, doses which were also maternally toxic, following daily intravenous dosing during the period of organogenesis. The no-observable-effect levels for embryotoxicity in rats (0.5 mg/kg/day) and in rabbits (0.25 mg/kg/day) were approximately 0.04 and 0.05 times the clinical dose (5 mg/kg every other week) based on AUC, respectively. An increased incidence of fetal external, soft tissue and skeletal anomalies (<span class="product-label-link" type="condition" conceptid="4062639" conceptname="Meningocele">meningocele</span>, short snout, and short maxillary bones) occurred in rabbits at the high dose (1 mg/kg/day) which was also maternally toxic. There are no adequate and well controlled studies in pregnant women. Cidofovir injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_845fefec-4a98-4f1f-98eb-c3487fef1d8a"></a><a name="section-9.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether cidofovir is excreted in human milk. Since many drugs are excreted in human milk and because of the potential for adverse reactions as well as the potential for tumorigenicity shown for cidofovir in animal studies, cidofovir injection should not be administered to nursing mothers. The U.S. Public Health Service Centers for Disease Control and Prevention advises HIV-infected women not to breast-feed to avoid postnatal transmission of HIV to a child who may not yet be infected.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_075cc6eb-e0b0-4789-8e29-2fe59f88101b"></a><a name="section-9.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in children have not been studied. The use of cidofovir injection in children with AIDS warrants extreme caution due to the risk of long-term carcinogenicity and reproductive toxicity. Administration of cidofovir injection to children should be undertaken only after careful evaluation and only if the potential benefits of treatment outweigh the risks.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_86f7af70-0378-498d-82f7-f9376bab16e0"></a><a name="section-9.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No studies of the safety or efficacy of cidofovir injection in patients over the age of 60 have been conducted. Since elderly individuals frequently have reduced glomerular filtration, particular attention should be paid to assessing renal function before and during cidofovir injection administration (see <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_c49376b6-119a-40e2-9fb7-4c19cd155583"></a><a name="section-10"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span>:</span></span> Renal toxicity, as manifested by ≥ 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, serum creatinine elevations of ≥ 0.4 mg/dL, or decreased creatinine clearance ≤ 55 mL/min, occurred in 79 of 135 (59%) patients receiving cidofovir injection at a maintenance dose of 5 mg/kg every other week. Maintenance dose reductions from 5 mg/kg to 3 mg/kg due to <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> or serum creatinine elevations were made in 12 of 41 (29%) patients who had not received prior therapy for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> (Study 106) and in 19 of 74 (26%) patients who had received prior therapy for <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> (Study 107). Prior foscarnet use has been associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>; therefore, such patients must be monitored closely (see <a href="#i4i_contraindications_id_3c964b31-bd5b-4c97-882a-2249cbdb5caa">CONTRAINDICATIONS</a>, <a href="#i4i_warnings_id_7790e239-8cd5-4765-ac00-7d686751bf4f">WARNINGS</a>, <a href="#i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69">DOSAGE AND ADMINISTRATION</a>).</dd>
<dt>2.</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>:</span></span> In clinical trials, at the 5 mg/kg maintenance dose, a decrease in absolute neutrophil count to ≤ 500 cells/mm<span class="Sup">3</span> occurred in 24% of patients. Granulocyte colony stimulating factor (GCSF) was used in 39% of patients.</dd>
<dt>3.</dt>
<dd>
<span class="Bold"><span class="Italics">Decreased Intraocular Pressure/Ocular Hypotony:</span></span> Among the subset of patients monitored for intraocular pressure changes, a ≥ 50% decrease from baseline intraocular pressure was reported in 17 of 70 (24%) patients at the 5 mg/kg maintenance dose. Severe hypotony (intraocular pressure of 0 to 1 mm Hg) has been reported in three patients. Risk of ocular hypotony may be increased in patients with preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus.</dd>
<dt>4.</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="434926" conceptname="Iridocyclitis">Anterior Uveitis</span>/<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">Iritis</span>:</span></span> <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> or <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> has been reported in clinical trials and during post-marketing in patients receiving cidofovir injection therapy. <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">Uveitis</span> or <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> was reported in 15 of 135 (11%) patients receiving 5 mg/kg maintenance dosing. Treatment with topical corticosteroids with or without topical cycloplegic agents may be considered. Patients should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>/<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> during cidofovir injection therapy.</dd>
<dt>5.</dt>
<dd>
<span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span>:</span></span> A diagnosis of Fanconi's syndrome, as manifested by multiple abnormalities of proximal renal tubular function, was reported in 1% of patients. Decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> to ≤ 16 mEq/L occurred in 16% of cidofovir-treated patients. Cases of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in association with liver dysfunction and <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> have been reported in patients receiving cidofovir injection.</dd>
</dl>
<p class="First">In clinical trials, cidofovir injection was withdrawn due to adverse events in 39% of patients treated with 5 mg/kg every other week as maintenance therapy. </p>
<p>The incidence of adverse reactions reported as serious in three controlled clinical studies in patients with <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span>, regardless of presumed relationship to drug, is listed in Table 4. </p>
<a name="_Refid_9943b5bb-494a-488f-984f-f0c7db8e7"></a><table>
<caption><span>Table 4: Serious Clinical Adverse Events or Laboratory Abnormalities Occurring in &gt; 5% of Patients</span></caption>
<col width="43%">
<col width="7%">
<col width="9%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Rrule Toprule" colspan="2">
<span class="Bold">N = 135</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a><br><span class="Bold"># patients (%)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Patients receiving 5 mg/kg maintenance regimen in Studies 105, 106 and 107.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Defined as decreased intraocular pressure (IOP) to ≤ 50% that at baseline. Based on 70 patients receiving 5 mg/kg maintenance dosing (Studies 105, 106 and 107), for whom baseline and follow-up IOP determinations were recorded.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> (≥ 100 mg/dL)</p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First">68</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">(50)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (≤ 500 cells/mm<span class="Sup">3</span>)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">33</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Decreased Intraocular Pressure<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">17</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Decreased Serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> (≤ 16 mEq/L)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(16)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">19</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(14)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(12)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Creatinine Elevation (≥ 2.0 mg/dL)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">16</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(12)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">12</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">11</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(8)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">10</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(7)</p></td>
</tr>
</tbody>
</table>
<p>The most frequently reported adverse events regardless of relationship to study drugs (cidofovir or probenecid) or severity are shown in Table 5. </p>
<p>The following additional list of adverse events/intercurrent illnesses have been observed in clinical studies of cidofovir injection and are listed below regardless of causal relationship to cidofovir injection. Evaluation of these reports was difficult because of the diverse manifestations of the underlying disease and because most patients received numerous concomitant medicines.</p>
<p><span class="Italics">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, AIDS, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, catheter blocked, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="440035" conceptname="Cryptococcosis">cryptococcosis</span>, <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cyst</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, flu-like syndrome, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reaction</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4318379" conceptname="Disorder of mucous membrane">mucous membrane disorder</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></p>
<p><span class="Italics">Cardiovascular System</span>: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">cardiovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="321052" conceptname="Peripheral vascular disease">peripheral vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">vascular disorder</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Italics">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="195856" conceptname="Cholangitis">cholangitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">gingivitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4279681" conceptname="Hepatosplenomegaly">hepatosplenomegaly</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, abnormal liver function, <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, <span class="product-label-link" type="condition" conceptid="79069" conceptname="Disorder of rectum">rectal disorder</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="138463" conceptname="Aphthous ulcer of mouth">aphthous stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, <span class="product-label-link" type="condition" conceptid="133228" conceptname="Dental caries">tooth caries</span></p>
<p><span class="Italics">Endocrine System:</span> <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal cortex insufficiency</span></p>
<p><span class="Italics">Hemic and Lymphatic System</span>: <span class="product-label-link" type="condition" conceptid="4195171" conceptname="Normocytic hypochromic anemia">hypochromic anemia</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4027114" conceptname="Pseudolymphoma">lymphoma like reaction</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, splenic disorder, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span></p>
<p><span class="Italics">Metabolic and Nutritional System</span>: <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">cachexia</span>, <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemic reaction</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">hypomagnesemia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>, <span class="product-label-link" type="condition" conceptid="4228222" conceptname="Hypoproteinemia">hypoproteinemia</span>, increased alkaline phosphatase, increased BUN, increased lactic dehydrogenase, increased <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>, increased SGPT, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span></p>
<p><span class="Italics">Musculoskeletal System</span>: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>, <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">bone necrosis</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">joint disorder</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span>, <span class="product-label-link" type="condition" conceptid="73571" conceptname="Pathological fracture">pathological fracture</span></p>
<p><span class="Italics">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">acute brain syndrome</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="374923" conceptname="Bell's palsy">facial paralysis</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="374022" conceptname="Hemiplegia">hemiplegia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, hypotony, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">increased libido</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441553" conceptname="Myoclonus">myoclonus</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="Italics">Respiratory System</span>: <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccup</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, increased <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">larynx edema</span>, <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disorder</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="253796" conceptname="Pneumothorax">pneumothorax</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></p>
<p><span class="Italics">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4220002" conceptname="Furuncle">furunculosis</span>, herpes simplex, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">seborrhea</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, skin <span class="product-label-link" type="condition" conceptid="4210465" conceptname="Hypertrophy">hypertrophy</span>, <span class="product-label-link" type="condition" conceptid="4262920" conceptname="Skin ulcer">skin ulcer</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p>
<p><span class="Italics">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4270897" conceptname="Corneal lesion">corneal lesion</span>, <span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, <span class="product-label-link" type="condition" conceptid="201577" conceptname="Degenerative and vascular disorders of ear">ear disorder</span>, <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">eye disorder</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>, <span class="product-label-link" type="condition" conceptid="378163" conceptname="Hyperacusis">hyperacusis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="380727" conceptname="Transient refractive change">refraction disorder</span>, <span class="product-label-link" type="condition" conceptid="378414" conceptname="Retinal detachment">retinal detachment</span>, <span class="product-label-link" type="condition" conceptid="378416" conceptname="Retinal disorder">retinal disorder</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span></p>
<p><span class="Italics">Urogenital System</span>: decreased creatinine clearance, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stone</span>, <span class="product-label-link" type="condition" conceptid="4163232" conceptname="Mastitis">mastitis</span>, metorrhagia, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="196734" conceptname="Disorder of prostate">prostatic disorder</span>, toxic nephrophathy, <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span>, <span class="product-label-link" type="condition" conceptid="442282" conceptname="Urinary casts">urinary casts</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></p>
<a name="_Refid_64af4e51-72e5-4a0c-afbe-780d14bd1"></a><table>
<caption><span>Table 5: All Clinical Adverse Events, Laboratory Abnormalities or Intercurrent Illnesses Regardless of Severity Occurring in &gt; 15% of Patients</span></caption>
<col width="35%">
<col width="7%">
<col width="9%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Rrule Toprule" colspan="2">
<span class="Bold">N = 115</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a><br><span class="Bold"># patients (%)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Patients receiving 5 mg/kg maintenance regimen in Studies 106 and 107.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Any Adverse Event</p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First">115</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">(100)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> (≥ 30 mg/dL)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">101</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(88)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> +/- <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">79</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(69)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">67</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(58)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (&lt; 750 cells/mm<span class="Sup">3</span>)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">50</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(43)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">50</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(43)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(30)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">34</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(30)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">32</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">31</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(27)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">30</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(26)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">29</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(25)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Creatinine Elevation (&gt; 1.5 mg/dL)</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(24)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">26</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(23)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">25</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(22)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">22</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(19)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral Moniliasis</span></p></td>
<td class="Botrule" align="center" valign="top"><p class="First">21</p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">(18)</p></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_37d0d26c-ce7f-4bec-80a4-393719cab141"></a><a name="section-10.1"></a><p></p>
<h2>Reporting of Adverse Reactions</h2>
<p class="First">To report SUSPECTED ADVERSE REACTIONS, contact Drug Safety at 1-888-875-1671 or FDA Medwatch at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a5e9742a-9f0b-4a4e-ae71-9fb2dd32c96a"></a><a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Two cases of cidofovir <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been reported. These patients received single doses of cidofovir injection at 16.3 mg/kg and 17.4 mg/kg, respectively, with concomitant oral probenecid and intravenous hydration. In both cases, the patients were hospitalized and received oral probenecid (one gram 3 times daily) and vigorous intravenous hydration with normal saline for 3 to 5 days. Significant changes in renal function were not observed in either patient.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_9bc06904-b284-4dd9-a079-e6adc2bcdd69"></a><a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">CIDOFOVIR INJECTION MUST NOT BE ADMINISTERED BY INTRAOCULAR INJECTION.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6cd07b3d-a937-4651-b6a4-4435d084b05e"></a><a name="section-12.1"></a><p></p>
<h2>Dosage</h2>
<p class="First">THE RECOMMENDED DOSAGE, FREQUENCY, OR INFUSION RATE MUST NOT BE EXCEEDED. CIDOFOVIR INJECTION MUST BE DILUTED IN 100 MILLILITERS 0.9% (NORMAL) SALINE PRIOR TO ADMINISTRATION. TO MINIMIZE POTENTIAL <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span>, PROBENECID AND INTRAVENOUS SALINE PREHYDRATION MUST BE ADMINISTERED WITH EACH CIDOFOVIR INJECTION INFUSION.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c830daeb-097a-45f1-899b-5f70d7ec5184"></a><a name="section-12.2"></a><p></p>
<h2>Induction Treatment</h2>
<p class="First">The recommended induction dose of cidofovir injection for patients with a serum creatinine of ≤ 1.5 mg/dL, a calculated creatinine clearance &gt; 55 mL/min, and a urine protein &lt; 100 mg/dL (equivalent to &lt; 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>) is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over 1 hr) administered once weekly for two consecutive weeks. </p>
<p>Because serum creatinine in patients with advanced AIDS and <span class="product-label-link" type="condition" conceptid="4330151" conceptname="Cytomegaloviral retinitis">CMV retinitis</span> may not provide a complete picture of the patient's underlying renal status, it is important to utilize the Cockcroft-Gault formula to more precisely estimate creatinine clearance (Cr<span class="Sub">Cl</span>). As creatinine clearance is dependent on serum creatinine and patient weight, it is necessary to calculate clearance prior to initiation of cidofovir injection. Cr<span class="Sub">Cl</span> (mL/min) should be calculated according to the following formula:</p>
<table>
<col width="34%">
<col width="40%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule" valign="top"><p class="First">Creatinine clearance for males =</p></td>
<td class="Botrule Toprule" align="center" valign="top"><p class="First">[140-age (years)] × [body wt (kg)]</p></td>
</tr>
<tr>
<td valign="top"></td>
<td align="center" valign="top"><p class="First">72 × [serum creatinine (mg/dL)]</p></td>
</tr>
<tr>
<td valign="top"><p class="First">Creatinine clearance for females =</p></td>
<td class="Botrule" align="center" valign="top"><p class="First">[140-age (years)] × [body wt (kg)]× 0.85</p></td>
</tr>
<tr class="Last">
<td class="Botrule" valign="top"></td>
<td class="Botrule" align="center" valign="top"><p class="First">72 × [serum creatinine (mg/dL)]</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d4ac1aa1-eb65-4d01-9450-1358c9b26100"></a><a name="section-12.3"></a><p></p>
<h2>Maintenance Treatment</h2>
<p class="First">The recommended maintenance dose of cidofovir injection is 5 mg/kg body weight (given as an intravenous infusion at a constant rate over one hr), administered once every 2 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6f7fb4d-1105-48f3-8d4c-9653ceed2a66"></a><a name="section-12.4"></a><p></p>
<h2>Dose Adjustment</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39371e35-079d-40ad-847b-eb84d8124281"></a><a name="section-12.4.1"></a><p></p>
<h3>Changes in Renal Function During Cidofovir Injection Therapy</h3>
<p class="First">The maintenance dose of cidofovir injection must be reduced from 5 mg/kg to 3 mg/kg for an increase in serum creatinine of 0.3 to 0.4 mg/dL above baseline. Cidofovir injection therapy must be discontinued for an increase in serum creatinine of ≥ 0.5 mg/dL above baseline or development of ≥ 3+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a258064b-083d-4d73-8ba0-32891630dc89"></a><a name="section-12.4.2"></a><p></p>
<h3>Preexisting <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h3>
<p class="First">Cidofovir injection is contraindicated in patients with a serum creatinine concentration &gt; 1.5 mg/dL, a calculated creatinine clearance ≤ 55 mL/min, or a urine protein ≥ 100 mg/dL (equivalent to ≥ 2+ <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_774fce7b-f2c9-4e17-b29e-01d8117462cf"></a><a name="section-12.5"></a><p></p>
<h2>Probenecid</h2>
<p class="First">Probenecid must be administered orally with each cidofovir injection dose. Two grams must be administered 3 hr prior to the cidofovir injection dose and one gram administered at 2 and again at 8 hr after completion of the one hr cidofovir injection infusion (for a total of 4 grams).</p>
<p>Ingestion of food prior to each dose of probenecid may reduce drug-related <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. Administration of an antiemetic may reduce the potential for <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> associated with probenecid ingestion. In patients who develop allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> symptoms to probenecid, the use of an appropriate <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> or therapeutic antihistamine and/or acetaminophen should be considered (see <a href="#i4i_contraindications_id_3c964b31-bd5b-4c97-882a-2249cbdb5caa">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec543f82-c4ab-4b8e-9c38-280914c63734"></a><a name="section-12.6"></a><p></p>
<h2>Hydration</h2>
<p class="First">Patients must receive at least one liter of 0.9% (normal) saline solution intravenously with each infusion of cidofovir injection. The saline solution should be infused over a 1 to 2 hr period immediately before the cidofovir injection infusion. Patients who can tolerate the additional fluid load should receive a second liter. If administered, the second liter of saline should be initiated either at the start of the cidofovir injection infusion or immediately afterwards, and infused over a 1 to 3 hr period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ef14dcb3-190e-4dfa-a5a8-c2b619a345d2"></a><a name="section-12.7"></a><p></p>
<h2>Method of Preparation and Administration</h2>
<p class="First">Inspect vials visually for particulate matter and discoloration prior to administration. If particulate matter or discoloration is observed, the vial should not be used. With a syringe, extract the appropriate volume of cidofovir injection from the vial and transfer the dose to an infusion bag containing 100 mL 0.9% (normal) saline solution. Infuse the entire volume intravenously into the patient at a constant rate over a one hr period. Use of a standard infusion pump for administration is recommended.</p>
<p>It is recommended that cidofovir injection infusion admixtures be administered within 24 hr of preparation and that refrigerator or freezer storage not be used to extend this 24 hr limit.</p>
<p>If admixtures are not intended for immediate use, they may be stored under refrigeration (2°C to 8°C) for no more than 24 hr. Refrigerated admixtures should be allowed to equilibrate to room temperature prior to use.</p>
<p>The chemical stability of cidofovir injection admixtures was demonstrated in polyvinyl chloride composition and ethylene/propylene copolymer composition commercial infusion bags, and in glass bottles. <span class="Bold">No data are available to support the addition of other drugs or supplements to the cidofovir admixture for concurrent administration.</span></p>
<p>Cidofovir Injection is supplied in single-use vials. Partially used vials should be discarded (see Handling and Disposal).</p>
<p><span class="Bold">Compatibility with Ringer's solution, Lactated Ringer's solution or bacteriostatic infusion fluids has not been evaluated.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_81eaba42-59e3-4f02-9586-14a210153ccd"></a><a name="section-12.8"></a><p></p>
<h2>Handling and Disposal</h2>
<p class="First">Due to the mutagenic properties of cidofovir, adequate precautions including the use of appropriate safety equipment are recommended for the preparation, administration, and disposal of cidofovir injection. The National Institutes of Health presently recommends that such agents be prepared in a Class II laminar flow biological safety cabinet and that personnel preparing drugs of this class wear surgical gloves and a closed front surgical-type gown with knit cuffs. If cidofovir injection contacts the skin, wash membranes and flush thoroughly with water. Excess cidofovir injection and all other materials used in the admixture preparation and administration should be placed in a leak-proof, puncture-proof container. The recommended method of disposal is <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperature</span> incineration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_abfc5d46-6e00-463f-872a-d7681a00b48b"></a><a name="section-12.9"></a><p></p>
<h2>Patient Monitoring</h2>
<p class="First">Serum creatinine and urine protein must be monitored within 48 hours prior to each dose. White blood cell counts with differential should be monitored prior to each dose. In patients with <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, intravenous hydration should be administered and the test repeated. Intraocular pressure, visual acuity and ocular symptoms should be monitored periodically.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_aaa77432-b31c-4809-8a21-f069e09fb55f"></a><a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cidofovir Injection, 75 mg per mL, for intravenous infusion, is available in:</p>
<p>NDC 67457-210-05<br>5 mL (375 mg) single-use vial, packaged individually.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Preservative Free</span></p>
<p>Sterile. Non-pyrogenic.</p>
<p>Discard unused portion.</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_bad7c22b-206e-4a90-a244-4b54be92b89f"></a><a name="section-14"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Ho HT, Woods KL, Bronson JJ, De Boeck H, Martin JC and Hitchcock MJM. Intracellular Metabolism of the Antiherpesvirus Agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy) propyl]cytosine. <span class="Italics">Mol Pharmacol</span><span class="Bold"> 41</span>:197–202, 1992.</dd>
<dt>2.</dt>
<dd>Cherrington JM, Allen SJW, McKee BH, and Chen MS. Kinetic Analysis of the Interaction Between the Diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, zalcitabineTP, zidovudineTP, and FIAUTP with Human DNA Polymerases b and g. <span class="Italics">Biochem Pharmacol</span><span class="Bold"> 48</span>:1986–1988, 1994.</dd>
<dt>3.</dt>
<dd>Xiong X, Smith JL, Kim C, Huang E, and Chen MS. Kinetic Analysis of the Interaction of Cidofovir Diphosphate with Human Cytomegalovirus DNA Polymerase. <span class="Italics">Biochem Pharmacol</span><span class="Bold"> 51</span>:1563–1567, 1996.</dd>
<dt>4.</dt>
<dd>Cherrington JM, Mulato AS, Fuller MD, Chen MS. <span class="Italics">In Vitro</span> Selection of a Human Cytomegalovirus (HCMV) that is Resistant to Cidofovir. 35th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. Abstract H117, 1995.</dd>
<dt>5.</dt>
<dd>Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, and Biron KK. Ganciclovir-Resistant Cytomegalovirus Clinical Isolates: Mode of Resistance to Ganciclovir. <span class="Italics">Antimicrob Agents Chemother </span><span class="Bold"> 35</span>:2191–2197, 1991.</dd>
<dt>6.</dt>
<dd>Sullivan V, Biron KK, Talarico C, Stanat SC, Davis M, Pozzi M, and Coen DM. A Point Mutation in the Human Cytomegalovirus DNA Polymerase Gene Confers Resistance to Ganciclovir and phosphonylmethoxyalkyl Derivatives. <span class="Italics">Antimicrob Agents Chemother</span><span class="Bold"> 37</span>:19–25, 1993.</dd>
<dt>7.</dt>
<dd>Tatarowicz WA, Lurain NS, and Thompson KD. A Ganciclovir-Resistant Clinical Isolate of Human Cytomegalovirus Exhibiting Cross-Resistance to other DNA Polymerase Inhibitors. <span class="Italics">J Infect Dis</span><span class="Bold"> 166</span>:904–907, 1992.</dd>
<dt>8.</dt>
<dd>Lurain NS, Thompson KD, Holmes EW, and Read GS. Point Mutations in the DNA Polymerase Gene of Human Cytomegalovirus that Result in Resistance to Antiviral Agents. <span class="Italics">J Virol</span><span class="Bold"> 66</span>:7146–7152, 1992.</dd>
<dt>9.</dt>
<dd>Smith IL, Cherrington JM, Jiles RE, Fuller MD, Freeman WR, Spector SA. High-level Resistance of Cytomegalovirus to Ganciclovir is Associated with Alterations in both the UL97 and DNA Polymerase Genes. <span class="Italics">J Infect Dis</span><span class="Bold"> 176</span>:69–77, 1997.</dd>
<dt>10.</dt>
<dd>Sullivan V and Coen DM. Isolation of Foscarnet-Resistant Human Cytomegalovirus Patterns of Resistance and Sensitivity to Other Antiviral Drugs. <span class="Italics">J Infect Dis</span><span class="Bold"> 164</span>:781–784, 1991.</dd>
<dt>11.</dt>
<dd>Snoeck R, Andrei G, and De Clercq E. Patterns of Resistance and Sensitivity to Antiviral Compounds of Drug-Resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> of Human Cytomegalovirus Selected <span class="Italics">in Vitro. Eur J Clin Microbiol Infect Dis</span><span class="Bold"> 15</span>:574–579, 1996.</dd>
<dt>12.</dt>
<dd>Baldanti F, Underwood MR, Stanat SC, Biron KK, Chou S, Sarasini A, Silini E, and Gerna G. Single Amino Acid Changes in the DNA Polymerase Confer Foscarnet Resistance and Slow-Growth Phenotype, While Mutations in the UL97-Encoded Phosphotransferase Confer Ganciclovir Resistance in Three Double-Resistant Human Cytomegalovirus <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> Recovered from Patients with AIDS. <span class="Italics">J Virol</span><span class="Bold"> 70</span>:1390–1395, 1996.</dd>
<dt>13.</dt>
<dd>The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Cidofovir (HPMPC) for the Treatment of Cytomegalovirus <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">Retinitis</span> in Patients with AIDS: the HPMPC Peripheral Cytomegalovirus <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">Retinitis</span> Trial. <span class="Italics">Ann Intern Med</span><span class="Bold"> 126</span>:264–274, 1997.</dd>
<dt>14.</dt>
<dd>Lalezari JP, Stagg RJ, Kupperman BD, et al. Intravenous Cidofovir for Peripheral Cytomegalovirus <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">Retinitis</span> in Patients with AIDS. A Randomized, Controlled Trial. <span class="Italics">Ann Intern Med</span><span class="Bold"> 126</span>:257–263, 1997.</dd>
</dl>
<p class="First">Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p>REVISED NOVEMBER 2012<br>MI:CIDOIJ:R2</p>
<p>0782L101</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_94483370-ba8e-4fe7-b871-e3849a00dc2f"></a><a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Vial Label</h1>
<p class="First"><span class="Bold">NDC 67457-210-05     5 mL</span></p>
<p><span class="Bold">Cidofovir </span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">375 mg/5 mL</span><br>(75 mg/mL)</p>
<p><span class="Bold">For Intravenous Infusion Only</span></p>
<p><span class="Bold">DILUTE BEFORE USE</span></p>
<p><span class="Bold">Not for Intraocular </span><br><span class="Bold">Injection</span></p>
<p><span class="Bold">Rx only      Single-Use Vial</span></p>
<p><span class="Bold">Preservative Free</span></p>
<p>Sterile. Non-pyrogenic.</p>
<p>Discard unused portion.</p>
<p><span class="Bold">Each mL contains:</span> Cidofovir (anhydrous),<br>75 mg; water for injection, q.s. Sodium<br>hydroxide and/or hydrochloric acid may<br>have been added for pH adjustment.</p>
<p><span class="Bold">Usual Dosage: </span>See accompanying<br>prescribing information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See </span><br><span class="Bold">USP Controlled Room Temperature.]</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Institutional LLC</span><br>Rockford, IL 61103 U.S.A.</p>
<p>Manufactured by:<br><span class="Bold">Mylan Institutional</span><br>Galway, Ireland</p>
<p><span class="Bold">Mylan.com</span></p>
<p>MI:210:1C:R2</p>
<div class="Figure">
<a name="id1217"></a><img alt="Cidofovir Injection 375 mg/5 mL Carton Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=56541229-8c1a-4550-8951-2415ed08e7e9&amp;name=cdf09920-bfe5-407c-921f-f4aefca3e29e-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CIDOFOVIR 		
					</strong><br><span class="contentTableReg">cidofovir anhydrous injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:67457-210</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CIDOFOVIR</strong> (Cidofovir Anhydrous) </td>
<td class="formItem">Cidofovir Anhydrous</td>
<td class="formItem">75 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Hydrochloric Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:67457-210-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA201276</td>
<td class="formItem">06/03/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Institutional LLC
							(790384502)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>cdf09920-bfe5-407c-921f-f4aefca3e29e</div>
<div>Set id: 56541229-8c1a-4550-8951-2415ed08e7e9</div>
<div>Version: 5</div>
<div>Effective Time: 20121127</div>
</div>
</div> <div class="DistributorName">Mylan Institutional LLC</div></p>
</body></html>
